Newly Activated Clinical Trials

This is a listing of clinical trials recently activated by the University of Illinois Cancer Center Clinical Trials Office for patient enrollment. Click the study links below to learn details regarding the studies on clinicaltrials.gov. You can also search for other clinical trials on our website. For more information or questions about a study, email [email protected] or call 312-355-5112.

---

Protocol Title: M22-574: A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

Sponsor: AbbVie

Principal Investigator: Matias Sanchez, MD

---

Protocol Title: R3767-ONC-2235: A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 antibody) in Combination With Cemiplimab (Anti-PD-1 antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 Greater Than or Equal to 50%

Sponsor: Regeneron

+

Protocol Title: R3767-ONC-2236: A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels

Sponsor: Regeneron

+

Protocol Title: J3M-MC-JZQB: SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression Greater Than or Equal to 50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression

Sponsor: Eli Lilly and Company

Principal Investigator for all three studies: Frank Weinberg, MD, PhD

---